Dutch medical software company Aiosyn raises €2.4M to advance cancer diagnostics through AI

Nijmegen, the Netherlands-based Aiosyn, a medical software company specialising in AI-powered pathology, has raised €2.4M in a funding round.

Participating investors are TNO Ventures, Oost NL, LUMO Labs, and Health Innovations.

Besides funding, the Dutch company also announced a strategic partnership with TNO, the Netherlands’ largest research and technology organisation.

The new funding will enable Aiosyn to accelerate the development and rollout of its AI-driven diagnostic solutions, aimed at improving cancer care through more efficient and precise pathology workflows.

Patrick de Boer, CEO and co-founder of Aiosyn, says, “This funding marks a major milestone for Aiosyn and reinforces our mission to bring AI innovation into clinical practice and invest in a new generation of AI algorithms that transform clinical decision-making for cancer patients”.

Partnership with TNO

This partnership will allow Aiosyn to use TNO’s research facilities and network to speed up the clinical testing and market launch of its AI software.

At the same time, TNO will benefit from Aiosyn’s advanced AI skills, helping it improve its preclinical contract research services.

“Aiosyn exemplifies the kind of bold, forward-thinking innovation that TNO is proud to support, delivering on TNO’s strategy to help Dutch tech companies scale globally and lead in key technologies”, says Hans Boumans, Director of TNO Ventures.

Aiosyn: Building AI-powered precision pathology software

Led by Patrick de Boer, Aiosyn aims to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients globally.

The company is a spin-off of the Computational Pathology Group of the Radboudumc in Nijmegen, the Netherlands. 

This group claims to be one of the leading Digital Pathology and AI teams in the world and is deeply rooted in the pathology practice.

By automating complex diagnostic tasks, the company’s AI solutions enable pathologists to deliver faster, more consistent results, ultimately improving outcomes for cancer patients.

Aiosyn’s algorithms are designed to enhance both the speed and precision of pathology workflows.

As a result, it helps to reduce healthcare costs and deliver more actionable insights for clinicians.

With this funding, Aiosyn will expand its portfolio to include novel AI-powered digital pathology biomarkers and advanced tools for preclinical image analysis.